A carregar...

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

Imatinib mesylate (IM), an original Abl tyrosine kinase inhibitor, entered the clinics in 1998 for the treatment of patients with chronic myeloid leukemia (CML). The drug is universally considered the treatment of choice for most, if not all, patients with CML. Importantly, lessons learned from pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mughal, Tariq I, Schrieber, Andrew
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3010822/
https://ncbi.nlm.nih.gov/pubmed/21209726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S5775
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!